WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
David E. I. PyottDirector2025-03-247,440$299.00
$2.22MSell
David E. I. PyottDirector2025-03-247,440$88.95
$661.79kBuy
Pushkal GargCMO EVP Dev Med Affairs2025-03-245,445$42.22
$229.89kBuy
Pushkal GargCMO EVP Dev Med Affairs2025-03-245,445$300.00
$1.63MSell
Pushkal GargCMO EVP Dev Med Affairs2025-03-214,321$285.00
$1.23MSell
Amy W. SchulmanDirector2025-03-132,750$131.21
$360.83kBuy
Pushkal GargCMO EVP Dev Med Affairs2025-03-04343$240.92
$82.64kSell
Pushkal GargCMO EVP Dev Med Affairs2025-03-04120$242.70
$29.12kSell
Pushkal GargCMO EVP Dev Med Affairs2025-03-04198$241.60
$47.84kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2025-03-0471$242.93
$17.25kSell

1 of 29

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Capital World Investors12.82%16,600,525$4.27BInstitution
Ag Novartis11.43%14,800,620$3.81BInsider
Fmr LLC10.42%13,485,903$3.47BInstitution
Vanguard Group Inc9.84%12,733,399$3.27BInstitution
Sanofi8.15%10,554,134$2.71BInsider
Blackrock Inc7.64%9,885,257$2.54BInstitution
Capital Research Global Investors5.38%6,968,513$1.79BInstitution
Regeneron Pharmaceuticals Inc3.43%4,444,445$1.14BInstitution
T Rowe Price Investment Management Inc3.39%4,384,449$1.13BInstitution
Wellington Management Group LLP3.24%4,196,623$1.08BInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY82.31%17.69%Net SellingNet Selling
ARGX56.15%0.00%
ONC3.15%32.86%Net SellingNet Buying
BNTX21.14%0.00%
RPRX55.47%17.23%Net BuyingNet Buying
View Top Biotech Stocks

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 99.74% institutional shareholders, 21.43% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.43% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $3.90B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.